Back to Search
Start Over
Current and potential urological applications of botulinum toxin A
- Source :
- Nature Reviews Urology; September 2015, Vol. 12 Issue: 9 p519-533, 15p
- Publication Year :
- 2015
-
Abstract
- Botulinum toxin subtype A (BoNT-A) is a potent neurotoxin that can selectively modulate neurotransmitter release from nerve endings, resulting in muscular paralysis. BoNT-A might also act on sensory nerves, and have an anti-inflammatory effect. In the first urological use of BoNT-A, injection into the urethral sphincters of patients with detrusor–sphincter dyssynergia resulted in a reduction of urethral resistance and improved voiding efficiency. Subsequently, intravesical BoNT-A injections have received regulatory approval for treatment of neurogenic detrusor overactivity owing to spinal cord lesions or multiple sclerosis, and idiopathic overactive bladder in adults. BoNT-A has also been widely used to treat patients with the off-label indications of neurogenic or non-neurogenic voiding dysfunction and male lower urinary tract symptoms owing to BPH and bladder-neck dysfunction. Other indications for which urologists have applied BoNT-A injections include interstitial cystitis/bladder pain syndrome, bladder oversensitivity and chronic pelvic pain syndrome. BoNT-A is currently delivered as an intravesical injection; however, use of liposome encapsulated formulations is also beginning to show some therapeutic potential.
Details
- Language :
- English
- ISSN :
- 17594812 and 17594820
- Volume :
- 12
- Issue :
- 9
- Database :
- Supplemental Index
- Journal :
- Nature Reviews Urology
- Publication Type :
- Periodical
- Accession number :
- ejs41029978
- Full Text :
- https://doi.org/10.1038/nrurol.2015.193